ArticleMycopathologia2026
Susceptibility Profiles Among Sporothrix brasiliensis Genotypes in the Ongoing Zoonotic Sporotrichosis Epidemic in Brazil, Argentina and Paraguay.
Article in Mycopathologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Sporothrix brasiliensis is the predominant etiological agent of sporotrichosis in Brazil and has been progressively expanding its geographic distribution to other countries in South America. The human patients infected with S. brasiliensis usually respond favorably to antifungal therapy. However, therapeutic failure may occur, and management may be particularly challenging in cases of severe disease. We recently reported that at least seven S. brasiliensis genotypes circulate across South America. However, their biological and clinical relevance of this genetic diversity remains poorly understood. In this study, we investigated whether distinct S. brasiliensis genotypes are associated with reduced susceptibility to the main antifungal agents used in the treatment of human and animal sporotrichosis. A total of 92 clinical, veterinary, and environmental S. brasiliensis strains from Brazil, Paraguay and Argentina, genotyping them using a four-gene MLST scheme. Mating type was assessed as well as antifungal susceptibility according to the M38-A2 CLSI guidelines. Results were interpreted according to the established epidemiological cutoff values for S. brasiliensis. The isolates are clustered into six distinct genotypes, with mating type showing a strong association with phylogenetic clades. Non-wild type strains were identified across four haplotypes (H1, H2, H3 and H4) for all antifungal drugs tested. These non-wild type strains were isolated from six distinct Brazilian states and were not associated to a specific genetic background. Nevertheless, non-wild-type strains were predominantly detected among feline isolates, most of which originated from Minas Gerais and belonged to haplotype H2. However, because only a limited number of H2 isolates were included in this study, additional isolates from this haplotype are need to confirm this association. Together, these findings suggest that decreased antifungal susceptibility in S. brasiliensis is not genotype-restricted but may be influenced by host-related or epidemiological factors, particularly in the context of feline sporotrichosis.
Indexed as
Identifiers
42878983What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.